Bellerophon Therapeutics Stock Current Liabilities
Bellerophon Therapeutics fundamentals help investors to digest information that contributes to Bellerophon Therapeutics' financial success or failures. It also enables traders to predict the movement of Bellerophon Pink Sheet. The fundamental analysis module provides a way to measure Bellerophon Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bellerophon Therapeutics pink sheet.
Bellerophon |
Bellerophon Therapeutics Company Current Liabilities Analysis
Bellerophon Therapeutics' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current Bellerophon Therapeutics Current Liabilities | 8.07 M |
Most of Bellerophon Therapeutics' fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bellerophon Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
CompetitionIn accordance with the recently published financial statements, Bellerophon Therapeutics has a Current Liabilities of 8.07 M. This is 99.54% lower than that of the Health Care Equipment & Supplies sector and 98.51% lower than that of the Health Care industry. The current liabilities for all United States stocks is 99.9% higher than that of the company.
Bellerophon Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bellerophon Therapeutics' direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Bellerophon Therapeutics could also be used in its relative valuation, which is a method of valuing Bellerophon Therapeutics by comparing valuation metrics of similar companies.Bellerophon Therapeutics is currently under evaluation in current liabilities category among its peers.
Bellerophon Fundamentals
| Return On Equity | -1.39 | |||
| Return On Asset | -0.6 | |||
| Profit Margin | (2.20) % | |||
| Operating Margin | (2.48) % | |||
| Current Valuation | (9.32 M) | |||
| Shares Outstanding | 12.23 M | |||
| Shares Owned By Insiders | 3.97 % | |||
| Shares Owned By Institutions | 45.08 % | |||
| Number Of Shares Shorted | 90.45 K | |||
| Price To Earning | 5.33 X | |||
| Price To Book | 1.05 X | |||
| EBITDA | (22.39 M) | |||
| Net Income | (19.83 M) | |||
| Cash And Equivalents | 16.33 M | |||
| Cash Per Share | 1.71 X | |||
| Total Debt | 203 K | |||
| Debt To Equity | 0.05 % | |||
| Current Ratio | 3.12 X | |||
| Book Value Per Share | 0.46 X | |||
| Cash Flow From Operations | (17.77 M) | |||
| Short Ratio | 1.26 X | |||
| Earnings Per Share | (0.34) X | |||
| Target Price | 2.0 | |||
| Number Of Employees | 18 | |||
| Beta | 0.55 | |||
| Market Capitalization | 1.25 M | |||
| Total Asset | 7.93 M | |||
| Retained Earnings | (252.08 M) | |||
| Working Capital | 2.16 M | |||
| Current Asset | 29.45 M | |||
| Current Liabilities | 8.07 M | |||
| Z Score | -49.75 | |||
| Net Asset | 7.93 M |
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Other Consideration for investing in Bellerophon Pink Sheet
If you are still planning to invest in Bellerophon Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bellerophon Therapeutics' history and understand the potential risks before investing.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |